<DOC>
	<DOCNO>NCT00675896</DOCNO>
	<brief_summary>To compare efficacy Quetiapine SR versus placebo 8 week unipolar non-psychotic adult outpatient depression comorbid fibromyalgia . This measure last observation carry forward ( LOCF ) mean change baseline week 8 Hamilton Depression Scale ( HAM-D ) total score . For purpose study , response regard improvement depressive symptom define 50 % decrease HAM-D score 8 week . Furthermore , proportion patient achieve remission define HAM-D total score 7 end treatment . The anxiety comorbid symptom often associate major depression assess HAM-A ( 14 item ) scale . Proportion patient respond achieve remission anxiety symptom define respectively reduction 50 % HAM-A total score baseline HAM-A total score 7 end treatment .</brief_summary>
	<brief_title>A Study Quetiapine Fumarate Sustained Release Major Depression With Comorbid Fibromyalgia Syndrome</brief_title>
	<detailed_description>Secondary Endpoints include - Change baseline week 8 Brief Pain Inventory ( short form ) total score . - Changes baseline week 8 HAM-A total score Changes baseline week 8 CGI Severity illness score . Clinical Global Impression - Improvement ( CGI-I ) score randomisation Week 8 Change baseline Fibromyalgia Impact Questionnaire ( FIQ ) . Change baseline Sleep Scale Medical Outcome Study ( MOS ) . Change baseline Sheehan Disability Scale ( SDS ) . Change baseline Quality Life Enjoyment Satisfaction Questionnaire- Short Form ( Q-LES-Q-SF ) . Change baseline Patient Health Questionaire-15 ( PHQ-15 ) . Change baseline Global Assessment Scale ( GAS ) . The side effect tolerability profile Quetiapine SR dose range use study assess every visit follow initial visit .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients DSM IV diagnosis major depression fibromyalgia confirm use American College Rheumatology criterion . Male female age 18 65 . Patients score least 22 17item HAMD scale least 4 ( i.e. , moderately ill ) Clinical Global Impression ( CGI ) severity scale . Both criterion meet screen baseline ( Study Day 0 ) . Patients DSMIV Axis 1 disorder MDD Chronic Pain Disorder within 6 month enrolment . History inadequate response adequate treatment ( 6 week ) 2 class antidepressant current depressive episode . Patients , investigator 's opinion , pose risk suicide . History suicide attempt within 3 year enter study . Current depressive episode secondary general medical condition exclude Fibromyalgia . History presence bipolar disorder psychosis . Post traumatic stress disorder , anorexia nervosa bulimia nervosa . Patients diagnosis DSMIV Axis II disorder major impact patient 's current psychiatric status . Present DSM IV diagnosis substance abuse dependence within 6 month prior screen visit ( except dependence full remission , except caffeine , nicotine opiate dependence )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>major depression comorbid fibromyalgia .</keyword>
</DOC>